Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome
MONDO:0014089Also known as: MSPC, palmoplantar carcinoma, multiple self-healing, palmoplantar carcinoma, multiple self-healing; MSPC, CIDED, corneal intraepithelial dyskeratosis and ectodermal dysplasia, corneal intraepithelial dyskeratosis and ectodermal dysplasia, formerly
11 clinical trials for this condition and its sub-types, 4 tagged with Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer
Disease control Recruiting nowThis phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo aims to keep prostate cancer in check with lower chemo dose
Disease control Recruiting nowThis study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…
Phase 2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC